Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance

Taiwanese Journal of Obstetrics and Gynecology

Volumn 51, Issue 3, 2012, Pages 336-341

  Chuang, Yin Ting ^a   Chang, Chih Long ^a,b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

Partially platinum sensitive; Platinum sensitivity; Progression free interval; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TRABECTEDIN;

ALOPECIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 84867142221     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2012.07.003     Document Type: Review

References (49)

1. Kyrgiou M., Salanti G., Pavlidis N., Paraskevaidis E., Ioannidis J.P. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006, 98:1655-1663.
2. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989, 59:650-653.
3. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36:207-211.
4. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9:389-393.
5. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15:2183-2193.
6. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4:87-94.
7. Clamp A., Jayson G.C. Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer 2002, 86:2-4.
8. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007, 14:195-208.
9. Poveda A. Introduction. Trabectedin treatment in GYN cancers. Int J Gynecol Cancer 2011, 21:S1-S2.
10. Sehouli J., Alfaro V., González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Annals of Oncology 2012, 23:556-562.
11. Ledermann J.A., Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006, 5:341-354.
12. Pujade-Lauraine E., Vergote I., Pignata S., Kristensen G. Optimizing management of recurrent epithelial ovarian cancer with non-platinum-based chemotherapy. Clin Ovarian Cancer 2008, 1:139-140.
13. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106.
14. Kaye S.B. Management of partially platinum-sensitive relapsed ovarian cancer. Eur J Cancer Suppl 2008, 6:16-21.
15. Pfisterer J., Ledermann J.A. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006, 33:S12-S16.
16. Milović-Kovačević M., Stamatovic L., Popov I., Radošević-Jelić L., Kezic I. Platinum-sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel. Med Sci Monit 2010, 16:CR549-CR554.
17. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, and the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-4707.
18. Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P.A., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
19. Alberts D.S., Liu P.Y., Wilczynski S.P., Clouser M.C., Lopez A.M., Michelin D.P., et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008, 108:90-94.
20. Rapoport B.L., Vorobiof D.A., Slabber C., Alberts A.S., Hlophe H.S., Mohammed C. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009, 19:1137-1141.
21. Pignata S., Lauraine E.P., du Bois A., Pisano C. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 2010, 73:23-30.
22. Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007, 18(2):263-268.
23. Vasey P., Largillier R., Gropp M., Gebski V., Sandvei R., Elit L., et al. 18LBA. A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients. Eur J Cancer Suppl 2009, 7:11.
24. Power P., Stuart G., Oza A., Provencher D., Bentley J.R., Miller W.H., et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 2009, 114:410-414.
25. Gladieff L., Ferrero A., De Rauglaudre G., Brown C., Vasey P., Reinthaller A., et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology 2012, 23:1185-1189.
26. Monk B.J., Coleman R.L. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009, 19:S63-S67.
27. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-3322.
28. Gordon A.N., Tonda M., Sun S., Rackoff W., Doxil Study 30-49 Investigators Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1-8.
29. Colombo N., Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol/Hematol 2007, 64:129-138.
30. National Institute for Health and Clinical Excellence (NICE) guidance. TA91 ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review): Guidance. Available from: [accessed 02.01.12]. http://www.nice.org.uk/nicemedia/live/11554/33024/33024.pdf.
31. National Comprehensive Cancer Network. (NCCN) clinical practice guidelines in oncology. Ovarian cancer Version 2.2012. Available from: [accessed 02.01.12]. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf.
32. Horowitz N.S., Hua J., Gibb R.K., Mutch D.G., Herzog T.J. The role of topotecan for extending the platinum free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004, 94:67-73.
33. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995, 13:1584-1588.
34. See H.T., Freedman R.S., Kudelka A.P., Burke T.W., Gershenson D.M., Tangjitgamol S., et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005, 15:209-216.
35. Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Selvaggi L., et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Oncology 2006, 71:320-326.
36. MITO-8: ClinicalTrials.gov Identifier: NCT00657878 ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/results?term=NCT00657878.
37. van Kesteren Ch, de Vooght M.M., López-Lázaro L., Mathôt R.A., Schellens J.H., Jimeno J.M., et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003, 14:487-502.
38. Garcia-Carbonero R., Supko J.G., Maki R.G., Manola J., Ryan D.P., Harmon D., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. Clin Oncol 2005, 23:5484-5492.
39. Carter N.J., Keam S.J. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007, 67:2257-2276.
40. Boudou L., Baconnier M., Blay J.Y., Lombard-Bohas C., Cassier P.A. Trabectedin for the management of soft-tissue sarcoma. Expert Rev Anticancer Ther 2009, 9:727-737.
41. Ganjoo K.N., Patel S.R. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother 2009, 10:2735-2743.
42. Sessa C., De Braud F., Perotti A., Bauer J., Curigliano G., Noberasco C., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005, 23:1867-1874.
43. Krasner C.N., McMeekin D.S., Chan S., Braly P.S., Renshaw F.G., Kaye S., et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum based regimens. Br J Cancer 2007, 97:1618-1624.
44. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009, 20:1794-1802.
45. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107-3114.
46. Colombo N. Efficacy of trabectedin in platinum-sensitive relapsed ovarian cancer-new data from the randomized OVA-301 Study. Int J Gynecol Cancer 2011, 21:S12-S16.
47. Poveda A., Vergote I., Tjulandin S., Kong B., Roy M., Chan S., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011, 22:39-48.
48. Kaye S.B., Colombo N., Monk B.J., Tjulandin S., Kong B., Roy M., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011, 22:49-58.
49. INOVATYON STUDY: ClinicalTrials.gov Identifier: NCT01379989. ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/results?term=NCT01379989.